Ardelyx, Inc. Sued for Securities Law Violations
DJS Law Group reminds investors of a class action lawsuit filed against Ardelyx, Inc. for alleged violations of securities laws. The suit claims the company issued misleading statements.
The DJS Law Group has announced a class action lawsuit filed against Ardelyx, Inc. (NASDAQ: ARDX) for alleged violations of federal securities laws. The lawsuit, covering the period from January 13, 2025, to August 6, 2026, claims the company made false and misleading statements to investors.
According to the complaint, Ardelyx experienced issues with delays in new patient starts and prescription fulfillment for its drugs XPHOZAH and IBSRELA. The lawsuit contends that these undisclosed problems made the company's public statements materially misleading throughout the class period.
Shareholders who purchased ARDX stock during the specified class period and incurred losses are encouraged to contact DJS Law Group to discuss their rights. While appointment as lead plaintiff is possible, it is not required to participate in any potential recovery.
The suit alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated by the U.S. Securities and Exchange Commission. The deadline for investors to join the case is November 16, 2026.